Related Experiment Videos
Therapeutic iron chelators and their potential side-effects
1Department of Pharmacy, King's College, University of London, U.K.
Biochemical Society Symposium
|January 1, 1995
Summary
New iron-chelating agents offer oral alternatives to desferrioxamine (DFO) for iron overload. However, all chelators, including hydroxypyridinones (HPO) and HBED, risk toxicity by disrupting iron balance or inhibiting metalloenzymes.
Area of Science:
- Pharmacology
- Biochemistry
- Toxicology
Background:
- Desferrioxamine (DFO) is the current standard for treating body iron overload.
- Oral iron-chelating agents are being developed as alternatives to DFO.
- These include hydroxypyridinones (HPO), desferrithiocin (DFT) analogues, and aminocarboxylate (HBED) chelators.
Purpose of the Study:
- To review potential toxic effects of new orally active iron-chelating agents.
- To discuss mechanisms of toxicity related to iron homeostasis disruption.
- To explore toxicity associated with metalloenzyme inhibition and iron complex formation.
Main Methods:
- Literature review of iron-chelating agents.
- Analysis of mechanisms of iron absorption, distribution, and utilization.
- Examination of iron-dependent metalloenzymes and iron complex toxicity.
Main Results:
- Iron-chelating agents can induce toxicity by altering iron homeostasis.
- Toxicity can occur via direct inhibition of non-heme iron-dependent enzymes like ribonucleotide reductase.
- Resultant iron complexes may cause toxicity through redox cycling and free radical generation.
Conclusions:
- Orally active iron chelators, while promising, carry inherent risks of toxicity.
- Understanding these toxic mechanisms is crucial for safe therapeutic development.
- Careful consideration of chelator design and iron complex properties is necessary.